Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Provides Response to New Minority Shareholder Announcement

Abstract:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today responded to the announcement by Silence Therapeutics plc that it acquired, in the open-market, an equity stake of 6,000,359 Arrowhead shares, representing 8.4% of the common shares outstanding. Arrowhead was advised of this just prior to the announcement by Silence.

Arrowhead Provides Response to New Minority Shareholder Announcement

Pasadena. CA | Posted on January 7th, 2017

There have been no discussions about any potential transaction between the two companies. Arrowhead's plans to develop its RNAi-based drug candidates ARO-HBV, ARO-AAT, ARO-F12, ARO-HIF2, ARO-LPA, ARO-AMG1, and other undisclosed programs, are unchanged and unaffected by this announcement. The company will also continue to seek partnerships and collaborations that maximize the value of its assets, as such opportunities may arise in the future.

Arrowhead president and CEO, Chris Anzalone, remarked, "We remain focused on advancing our programs in a way that maximizes stockholder value. While we welcome Silence as a stockholder, its recently announced stake in Arrowhead does not change our focus or strategic plans in any way."

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Pharmaceuticals, Inc.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

Investor Relations:
The Trout Group
Chad Rubin
646-378-2947

Media:
Russo Partners
Matt Middleman, M.D.
212-845-4272

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Enhancing the quantum sensing capabilities of diamond: Shooting electrons at diamonds can introduce quantum sensors into them November 24th, 2017

NanoSummit in Luxembourg: single wall carbon nanotubes have entered our lives as we approach a nanoaugmented future November 23rd, 2017

JPK reports on the exciting research in the School of Medicine at Sungkyunkwan University (SKKU), Suwon, South Korea using the NanoWizardŽ ULTRA Speed AFM to understand the binding of transcription factor Sox2 with super enhancers November 23rd, 2017

Precision NanoSystems to host nanomedicines roundtable November 23rd, 2017

Investments/IPO's/Splits

Nanometrics to Participate in the 6th Annual NYC Investor Summit 2017 November 16th, 2017

180 Degree Capital Corp. Leads Investment in TheStreet, Inc.; Investment Enables Removal of Capital Structure Overhang November 14th, 2017

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) October 23rd, 2017

Arrowhead Hosts Investor & Analyst R&D Day to Introduce TRiM(TM) Platform and Lead RNAi-based Drug Candidates September 14th, 2017

Nanomedicine

JPK reports on the exciting research in the School of Medicine at Sungkyunkwan University (SKKU), Suwon, South Korea using the NanoWizardŽ ULTRA Speed AFM to understand the binding of transcription factor Sox2 with super enhancers November 23rd, 2017

Precision NanoSystems to host nanomedicines roundtable November 23rd, 2017

Fine felted nanotubes : Research team of Kiel University develops new composite material made of carbon nanotubes November 22nd, 2017

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

Announcements

Enhancing the quantum sensing capabilities of diamond: Shooting electrons at diamonds can introduce quantum sensors into them November 24th, 2017

NanoSummit in Luxembourg: single wall carbon nanotubes have entered our lives as we approach a nanoaugmented future November 23rd, 2017

JPK reports on the exciting research in the School of Medicine at Sungkyunkwan University (SKKU), Suwon, South Korea using the NanoWizardŽ ULTRA Speed AFM to understand the binding of transcription factor Sox2 with super enhancers November 23rd, 2017

Precision NanoSystems to host nanomedicines roundtable November 23rd, 2017

Nanobiotechnology

JPK reports on the exciting research in the School of Medicine at Sungkyunkwan University (SKKU), Suwon, South Korea using the NanoWizardŽ ULTRA Speed AFM to understand the binding of transcription factor Sox2 with super enhancers November 23rd, 2017

Precision NanoSystems to host nanomedicines roundtable November 23rd, 2017

Fine felted nanotubes : Research team of Kiel University develops new composite material made of carbon nanotubes November 22nd, 2017

Nanoparticles could allow for faster, better medicine: Exposure of nanoparticles in the body allows for more effective delivery November 20th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project